CA2573129C - Procede pour la preparation de levofloxacine ou de son hydrate - Google Patents

Procede pour la preparation de levofloxacine ou de son hydrate Download PDF

Info

Publication number
CA2573129C
CA2573129C CA2573129A CA2573129A CA2573129C CA 2573129 C CA2573129 C CA 2573129C CA 2573129 A CA2573129 A CA 2573129A CA 2573129 A CA2573129 A CA 2573129A CA 2573129 C CA2573129 C CA 2573129C
Authority
CA
Canada
Prior art keywords
levofloxacin
water
mixed solvent
ethyl acetate
butanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2573129A
Other languages
English (en)
Other versions
CA2573129A1 (fr
Inventor
Tai-Au Lee
Ja-Heouk Khoo
Seong-Ho Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of CA2573129A1 publication Critical patent/CA2573129A1/fr
Application granted granted Critical
Publication of CA2573129C publication Critical patent/CA2573129C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention a trait à un procédé de préparation de semi-hydrate ou de monohydrate de lévofloxacine sans impuretés, c'est à dire les impuretés B, C, D, E, et F. Le procédé comprend: (a) l'ajout de lévofloxacine à un nouveau mélange de solvant; (b) l'ébullition au reflux du mélange obtenu en (a) pour former une solution; et (c) la récupération de semi-hydrate ou monohydrate de lévofloxacine à partir de la solution obtenue en (b).
CA2573129A 2004-07-21 2005-07-18 Procede pour la preparation de levofloxacine ou de son hydrate Expired - Fee Related CA2573129C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2004-0056637 2004-07-21
KR1020040056637A KR100704641B1 (ko) 2004-07-21 2004-07-21 고순도의 레보플록사신 제조방법
PCT/KR2005/002294 WO2006009374A1 (fr) 2004-07-21 2005-07-18 Procede pour la preparation de levofloxacine ou de son hydrate

Publications (2)

Publication Number Publication Date
CA2573129A1 CA2573129A1 (fr) 2006-01-26
CA2573129C true CA2573129C (fr) 2012-10-16

Family

ID=35785447

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2573129A Expired - Fee Related CA2573129C (fr) 2004-07-21 2005-07-18 Procede pour la preparation de levofloxacine ou de son hydrate

Country Status (4)

Country Link
JP (1) JP5065020B2 (fr)
KR (1) KR100704641B1 (fr)
CA (1) CA2573129C (fr)
WO (1) WO2006009374A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629458B2 (en) 2001-10-03 2009-12-08 Teva Pharmaceutical Industries Ltd. Preparation of levofloxacin and hemihydrate thereof
US7964723B2 (en) 2008-08-02 2011-06-21 Apeloa-Kangyu And practical process for exclusively producing (S)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido-[1,2,3,de][1,4]benzoxazine-6-carboxylic acid hemihydrate
CN110770353B (zh) 2017-04-23 2024-11-26 伊鲁米那股份有限公司 用于改进编索引的核酸文库中的样品鉴定的组合物和方法
CN111855840A (zh) * 2020-06-30 2020-10-30 辰欣药业股份有限公司 一种盐酸左氧氟沙星注射液中有关物质的检测方法
CN112174981A (zh) * 2020-11-03 2021-01-05 深圳市祥根生物科技有限公司 一种左氧氟沙星脱氟杂质的制备方法
CN116953096A (zh) * 2022-12-24 2023-10-27 华夏生生药业(北京)有限公司 一种左氧氟沙星注射液杂质检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777253A (en) * 1986-04-25 1988-10-11 Abbott Laboratories Process for preparation of racemate and optically active ofloxacin and related derivatives
JP3105572B2 (ja) * 1990-03-01 2000-11-06 第一製薬株式会社 水和物の選択的製法
TW208013B (fr) * 1990-03-01 1993-06-21 Daiichi Co Ltd
KR100309871B1 (ko) * 1999-02-24 2001-10-29 윤종용 (-)피리도벤즈옥사진 카르복실산 유도체의 제조방법
AU2002365416A1 (en) * 2001-11-29 2003-06-10 Teva Pharmaceutical Industries Ltd. Methods for the purification of levofloxacin
JP2004099494A (ja) * 2002-09-09 2004-04-02 Shiono Chemical Co Ltd 光学活性三環式化合物の製造方法
AU2003285625A1 (en) * 2002-12-16 2004-07-09 Ranbaxy Laboratories Limited Pure levofloxacin hemihydrate and processes for preparation thereof

Also Published As

Publication number Publication date
WO2006009374A1 (fr) 2006-01-26
CA2573129A1 (fr) 2006-01-26
JP5065020B2 (ja) 2012-10-31
JP2008507507A (ja) 2008-03-13
KR100704641B1 (ko) 2007-04-06
KR20060009155A (ko) 2006-01-31

Similar Documents

Publication Publication Date Title
JP5546539B2 (ja) バリオールアミンの立体選択的合成を行うための物質及び方法
CA2573129C (fr) Procede pour la preparation de levofloxacine ou de son hydrate
CN112154140B (zh) 化合物及其在合成布瓦西坦(Brivaracetam)原料药中的用途
CA2466860A1 (fr) Procedes de purification de levofloxacine
TWI777079B (zh) 稠合三環γ-胺基酸衍生物的製備方法及其中間體
CN111233866B (zh) 托法替尼或其盐的制备方法
KR102931600B1 (ko) 살리실아민 아세테이트 제조방법
CA2508341C (fr) Procede de preparation de derives de quinolonecarboxylate
KR101485418B1 (ko) 고순도 미르타자핀의 제조방법
Matsuyama et al. Conjugate addition of 6-membered hydrazine to chiral tert-butyl (E)-2-(p-tolylsulfinyl) cinnamates. Synthesis of (S)-celacinnine
KR100248370B1 (ko) (-)-3(s)-메틸피리도 벤즈옥사진 중간 유도체의 제조방법
JP2012020970A (ja) ｛２−アミノ−１，４−ジヒドロ−６−メチル−４−（３−ニトロフェニル）−３，５−ピリジンジカルボン酸３−（１−ジフェニルメチルアゼチジン−３−イル）エステル５−イソプロピルエステル｝の製造方法
KR960008243B1 (ko) 헤테로사이클릭 화합물
EP1817273B1 (fr) Procédé de préparation des diastéréoisomères de la 4-hydroxyisoleucine
KR20080021944A (ko) 광학활성 벤즈옥사진 유도체의 제조방법
CN107365299B (zh) 一种达比加群酯的制备方法及其中间体
KR20060125218A (ko) 광학활성 벤족사진 유도체의 제조방법
CN107652269A (zh) 甲磺酸氟马替尼中间体纯化方法
WO2026037241A1 (fr) Procédé de préparation d'un composé d'isoindoline, intermédiaire de celui-ci et procédé de préparation d'un intermédiaire
KR100209299B1 (ko) 새로운 아민고리 화합물
EP4703350A1 (fr) Procédé de préparation de 4-aminoindane et procédé de préparation de dihydroindényl-pyrazolo[3,4-b]pyridine-amine
KR101086177B1 (ko) 항균제인(-)-9-플루오르-2,3-디히드로-3(에스)-메틸-10-(4-메틸-1-피페라지닐)-7-옥소-7에이치-피리도[1,2,3-데]-1,4-벤즈옥사진-6-카르복실산의 새로운 제조 방법
WO2023100110A1 (fr) Procédé de préparation de brivaracétam
EP0497125B1 (fr) Procédé de préparation de 2'-diéthylaminorifamycine P (P/DEA)
KR100440192B1 (ko) 광학 활성 퀴놀론카르복실산 유도체의 제조방법

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220718